Research Topics
| Mario E LacoutureSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancerMario E Lacouture
Northwestern University, Chicago, IL, USA
J Clin Oncol 28:1351-7. 2010..This is the first study designed to examine differences between pre-emptive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhibitor...- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study groupMario E Lacouture
Dermatology Service, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering 53rd Street, 160 East 53rd Street, New York, NY 10022, USA
Support Care Cancer 18:509-22. 2010..We believe a class-specific grading scale is needed to help standardize assessment and improve reporting of EGFRI-associated dermatologic AEs... 
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesMario E Lacouture
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
Support Care Cancer 19:1079-95. 2011..The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities...- Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysisDavid Chu
Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, NY 11794 9447, USA
Clin Genitourin Cancer 7:11-9. 2009..86; 95% CI, 3.1-31.31; P < .001) in comparison with controls. There is a significant risk of developing HFSR in patients with cancer receiving sunitinib. Adequate monitoring and intervention are recommended for reducing the toxicity... - Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinibMario E Lacouture
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Oncologist 13:1001-11. 2008..Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy... - Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysisDavid Chu
Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
Acta Oncol 47:176-86. 2008..This study was conducted to determine the risk of developing HFSR among patients receiving sorafenib... - Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysisAlyx C Rosen
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 East 53rd Street, New York, New York 10022, USA
J Clin Endocrinol Metab 97:1125-33. 2012..Therefore, we conducted a systematic review and meta-analysis of the literature to determine the incidence and risk of developing a rash... 
Risk of skin rash associated with erlotinib in cancer patients: a meta-analysisYuxia Jia
Division of Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 9447, USA
J Support Oncol 7:211-7. 2009..72 (95% CI: 3.56-6.20) for erlotinib alone and 2.34 (95% CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy...- Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of lifeSmita S Joshi
Skin and Eye Reactions to Inhibitors of Epidermal Growth Factor Receptor and Kinase SERIES Clinic and Cancer Skin Care Program, Department of Dermatology and Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Cancer 116:3916-23. 2010..By using a dermatology-specific questionnaire, the authors examined the effect of these toxicities on QoL... - Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysisXiao Su
Department of Medicine, AtlantiCare Regional Medical Center, Atlantic City, NJ, USA
Oncology 77:124-33. 2009..Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash... - Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patientsBeatrice Nardone
Department of Dermatology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
Clin Cancer Res 16:4452-60. 2010.... - Skin care management in cancer patients: an evaluation of quality of life and tolerabilityAnn Cameron Haley
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Support Care Cancer 19:545-54. 2011..The objective of this study is to evaluate quality of life (QoL) and tolerability of three articles specifically developed for cancer skin care management (skin moisturizer, face moisturizer, and face wash)... - Economic burden of dermatologic adverse events induced by molecularly targeted cancer agentsJudy H Borovicka
Department of Dermatology, SERIES Clinic, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Arch Dermatol 147:1403-9. 2011..To report the financial impact of diagnosing and treating the dermatologic toxicities (dTs) that develop in patients receiving targeted anticancer therapies... - Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancerMario E Lacouture
Cancer Skin Care Program and SERIES Clinic, Department of Dermatology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill 60611 2941, USA
Cancer Nurs 30:S17-26. 2007..Effective management of these adverse effects may lessen the chance of suboptimal therapy and requires an understanding of the underlying pathophysiology, as well as knowledge of useful strategies for alleviating these effects... - Clinical management of EGFRI dermatologic toxicities: US perspectiveMario E Lacouture
Department of Dermatology, Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Oncology (Williston Park) 21:17-21. 2007..Two dermatologists who treat high numbers of patients affected by these EGFRI-induced cutaneous side effects submit their recommendations for management... - The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysisYevgeniy Balagula
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
Invest New Drugs 30:1773-81. 2012..1-6.2, p < 0.001). Despite sharing the same spectrum of target receptors with sorafenib and sunitinib, pazopanib is associated with an unexpectedly low risk of HFSR. Further investigations are needed to elucidate HFSR pathogenesis... - Dermatologic toxicities of targeted anticancer therapiesYevgeniy Balagula
Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
J Support Oncol 8:149-61. 2010.... - Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitorsPeggy A Wu
Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Curr Opin Oncol 23:343-51. 2011..These dermatologic toxicities have previously led to reduction or cessation of therapy and recently have been shown to decrease patients' quality of life... - Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitorsYevgeniy Balagula
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Dermatol 50:129-46. 2011..This review will describe the clinical presentation, histopathology, underlying mechanisms, and management options, emphasizing evidence-based approaches... - Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinibMinnelly Luu
Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Photodermatol Photoimmunol Photomed 23:42-5. 2007.... - The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysisBenjamin C Garden
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Am Acad Dermatol 67:400-8. 2012..The overall incidence and risk of nail changes associated with the use of epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature... - Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitorsYevgeniy Balagula
Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
Cancer 118:5078-83. 2012..Inhibitors of mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus, have been associated with a high rate of skin eruptions, but their clinical and histopathologic characteristics have not been explored... - Treatment of multiple keratoacanthomas with erlotinibDavid C Reid
Department of Dermatology, Feinberg School of Medicine, Northwestern University, 676 N St Clair St, Suite 1600, Chicago, IL 60611, USA
Int J Clin Oncol 15:413-5. 2010..This is the first report of multiple keratoacanthomas responding to therapy with an EGFR tyrosine kinase inhibitor, and it supports an emerging role for the use of EGFR inhibitors in the management of cutaneous malignancies... - Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapyR E Eilers
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611 2941, USA
J Natl Cancer Inst 102:47-53. 2010..We examined the prevalence of infections that complicate dermatologic toxic effects of EGFRIs... - Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trialsKimberly A Bauer
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Clin Colorectal Cancer 7:309-14. 2008..To improve patient counseling and prophylactic antitoxicity interventions, implementation of standards for reporting of dADRs is critical... - Unanticipated toxicities from anticancer therapies: survivors' perspectivesMona Gandhi
Department of Dermatology, Northwestern University s Feinberg School of Medicine, 676 N St Clair St, Suite 1600, Chicago, IL 60611, USA
Support Care Cancer 18:1461-8. 2010..These untoward events have not been examined from the survivors' perspective... - The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitorsMario E Lacouture
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
J Support Oncol 4:236-8. 2006 - Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey resultsSusan L Boone
Department of Dermatology, SERIES Clinic, Northwestern University s Feinberg School of Medicine, Chicago, Ill 60611, USA
Oncology 72:152-9. 2007..The survey results support that attentive cutaneous care is important in patients treated with EGFR inhibitors, and that proactive/combined interventions may enhance quality of life and optimize consistent drug administration... - Dermatologic challenges in cancer patients and survivorsRania Agha
Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Oncology (Williston Park) 21:1462-72; discussion 1473, 1476, 1481 passim. 2007..This review provides a basis for the understanding of dermatologic events in the oncology setting, in order to promote attentive care to cutaneous health in cancer patients and survivors... - Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)Yevgeniy Balagula
Dermatology Service, Department of Medicine, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering Cancer Center, 160 East 53rd Street, New York, NY 10022, USA
Invest New Drugs 29:1114-21. 2011..Similarly, their management may present a challenge in clinical trials. We reviewed the clinical presentation, evolution and management of dermatologic toxicities associated with selumetinib... - The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapiesYevgeniy Balagula
Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
J Am Acad Dermatol 65:624-35. 2011.... - Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelaeLynne I Wagner
Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Northwestern University, Feinberg Medical School, Chicago, IL 60611, USA
Oncology (Williston Park) 21:34-6. 2007..Cognitive behavioral strategies may also be useful in helping patients manage anxiety and depression associated with any changes in their social function caused by skin rash, as well as distress associated with having a cancer diagnosis... - Blackberry-induced hand-foot skin reaction to sunitinibSusan L Boone
Department of Dermatology, Northwestern University s Feinberg School of Medicine, Chicago, IL 60611, USA
Invest New Drugs 27:389-90. 2009.... - Analysis of dermatologic events in vemurafenib-treated patients with melanomaMario E Lacouture
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Oncologist 18:314-22. 2013..Conclusions. Dermatologic AEs associated with vemurafenib treatment in patients with melanoma were generally manageable with supportive care measures. Dose interruptions and/or reductions were required in <10% of patients... - The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of lifeBeatrice Nardone
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
J Drugs Dermatol 11:e61-5. 2012..The aim of this study is to evaluate the impact of HFSR associated with these multikinase inhibitors on patient health-related quality of life (HRQOL)... - Non-rash skin toxicities associated with novel targeted therapiesMario E Lacouture
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 48201, USA
Clin Lung Cancer 8:S36-42. 2006..This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment... - Mechanisms of cutaneous toxicities to EGFR inhibitorsMario E Lacouture
SERIES Clinic and Cancer Skin Care Program, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Suite 1600, Chicago, Illinois 60611, USA
Nat Rev Cancer 6:803-12. 2006..There is an urgent need for an improved understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, and to ensure quality of life and consistent antineoplastic therapy... - The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)Lynne I Wagner
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Support Care Cancer 21:1033-41. 2013..The Functional Assessment of Cancer Therapy (FACT)-EGFRI was developed to measure HRQL among patients receiving EGFRIs... - Characteristics of oral mucosal events related to bevacizumab treatmentIgor T Gavrilovic
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
Oncologist 17:274-8. 2012..We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab... - Dermatologic issues in adult survivors of childhood cancerKaren E Kinahan
Department of General Internal Medicine, Northwestern University, Chicago, IL, USA
J Cancer Surviv 3:158-63. 2009..Common late effects experienced by childhood cancer survivors include: thyroid disturbances, pulmonary compromise, heart failure, and secondary neoplasms. Dermatologic issues have been largely unexplored... - Hand-foot and stump syndrome to sorafenibSusan E Lai
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
J Clin Oncol 25:341-3. 2007 - Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year reviewDurga S Borkar
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Support Care Cancer 21:1167-74. 2013..The aim of this study is to describe common ocular adverse effects associated with EGFR inhibitor treatment, outline successful management options, and provide data on intermediate-term follow-up of these patients...